Non-qualified stock option

OUTFRONT Media Announces Pricing of Senior Secured Notes Offering

Retrieved on: 
Tuesday, November 7, 2023
Sale, Risk, Security (finance), Average revenue per user, NYSE, Tax, Health, Regulation, Transaction, REIT, Advertising, Senior, Outfront Media, Non-qualified stock option, Privacy, Pandemic, Annual report, Investment, Debt-to-GDP ratio, SEC Rule 144A, Failure

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- OUTFRONT Media Inc. (NYSE: OUT) today announced that two of its wholly-owned subsidiaries priced a private offering of $450.0 million in aggregate principal amount of 7.375% Senior Secured Notes due 2031 (the "notes").

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- OUTFRONT Media Inc. (NYSE: OUT) today announced that two of its wholly-owned subsidiaries priced a private offering of $450.0 million in aggregate principal amount of 7.375% Senior Secured Notes due 2031 (the "notes").
  • The offering is expected to close on November 20, 2023, subject to customary closing conditions.
  • OUTFRONT Media intends to use the net proceeds from the notes offering to redeem all of its outstanding 6.250% Senior Notes due 2025 (the "2025 notes") and to pay accrued and unpaid interest on the 2025 notes, if any, to, but excluding, the redemption date, to pay fees and expenses in connection with the notes offering and the 2025 notes redemption; and for general corporate purposes, which may include the repayment, refinancing, redemption or repurchase of existing indebtedness.
  • The notes will be guaranteed on a senior secured basis by OUTFRONT Media Inc. and each of its direct and indirect subsidiaries that guarantees its senior credit facilities.

NextEra Energy announces increased adjusted earnings per share expectations for 2022-2025 during investor conference

Retrieved on: 
Tuesday, June 14, 2022
Public expenditure, NextEra Energy, Leadership, Goal, Non-qualified stock option, Time, Insurance, Wind, LLC, U.S. Securities and Exchange Commission, Ethics, Transport, Fortune, Form 10-K, Ownership, Annual report, Income, Forward-looking statement, Nuclear Regulatory Commission, Nature, News, Policy, Failure, Nextera, NextEra Energy Resources, Maintenance, Multimedia, Natural gas, Sale, Growth, Electricity, NEE, Terrorism, Risk, Projection, Health, Private Securities Litigation Reform Act, NYSE, Compliance, Weather, Pandemic, Public policy, SEC, Phrase, NextEra Energy Partners, Industry, Epidemic, Electric Bond and Share Company v. Securities and Exchange Commission, View, Uncertainty, Renewable energy, LP

The members of the senior management team plan to discuss, among other things, that NextEra Energy is increasing its adjusted earnings per share expectations for 2022, 2023, 2024 and 2025, subject to the usual caveats.

Key Points: 
  • The members of the senior management team plan to discuss, among other things, that NextEra Energy is increasing its adjusted earnings per share expectations for 2022, 2023, 2024 and 2025, subject to the usual caveats.
  • NextEra Energy now expects adjusted earnings per share for 2022, 2023, 2024 and 2025 to be in the range of $2.80 to $2.90,$2.98to$3.13, $3.23 to $3.43and$3.45to$3.70, respectively.
  • NextEra Energy also uses earnings expressed in this fashion when communicating its financial results and earnings outlook to analysts and investors.
  • Forward-looking statements in this release include, among others, statements concerning adjusted earnings per share expectations and future operating performance.

Invesco Launches Digital Assets and Blockchain Thematic Equity ETFs in the U.S.

Retrieved on: 
Thursday, October 7, 2021
Crypto, Bitcoin, Blockchain Index, Theft, Investment banking, Fund of funds, Non-qualified stock option, Adoption, ETP, Securities Act of 1933, NYSE, Technology, Company, Income, Life, Marketing, Mining, TSX, Maintenance, Cboe Global Markets, S-Network Global Indexes, Solution, Prospectus, Multimedia, GBTC, Investment, Fund, Cryptocurrency, SATO, Acquisition, Risk, Galaxy Digital, Galaxy, Blockchain, Industry, Subsidiary, Benchmarking, CEO, Partnership, Research, Adviser, Equity, Internet, Security (finance)

ATLANTA, Oct. 7, 2021 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, today announced the launch of two passively managed exchange-traded funds (ETFs) focused on digital assets and blockchain.

Key Points: 
  • ATLANTA, Oct. 7, 2021 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, today announced the launch of two passively managed exchange-traded funds (ETFs) focused on digital assets and blockchain.
  • The Invesco Alerian Galaxy Crypto Economy ETF (SATO) and the Invesco Alerian Galaxy Blockchain Users and Decentralized Commerce ETF (BLKC) will offer thematic equity exposureto global public companies and select investment vehicles that are actively engaged in the cryptocurrency and blockchain sectors.
  • With offices in more than 20 countries, Invesco managed$1.5 trillionin assets on behalf of clients worldwide as ofJune 30, 2021.
  • Galaxy Digital is a diversified financial services and investment management company in the digital asset, cryptocurrency, and blockchain technology sectors.

DGAP-News: Steinhoff International Holdings N.V. :

Retrieved on: 
Wednesday, August 11, 2021
Frankfurt Stock Exchange, Music school, Plan, Company, JSE Limited, African, Hearing, DGAP, Travel, Review, Non-qualified stock option, Mayfair, News, SARB, Person, Claim, Proposal, COVID-19, FX, Western Cape Division, Steinhoff, Creditor, Life insurance, Insurance, Security (finance), Risk management, Pharmaceutical industry

(2) In addition, as announced on 14 February 2021, the settlement terms with Conservatorium include consideration payable by Steinhoff Africa Holdings Pty Limited (on behalf of SIHPL) in the amount EUR 61m.

Key Points: 
  • (2) In addition, as announced on 14 February 2021, the settlement terms with Conservatorium include consideration payable by Steinhoff Africa Holdings Pty Limited (on behalf of SIHPL) in the amount EUR 61m.
  • (3) The "SIHPL Contractual Claimants: Other" values in this table include the amount reserved in relation to Mayfair's disputed Contractual Claim against SIHPL.
  • All claimants are encouraged to support the further revised terms of the Steinhoff Litigation Settlement Proposal and to work with Steinhoff to conclude the approval process as soon as possible.
  • Claimants will be able to review additional information in relation to the Steinhoff Group global settlement and submit their claim details on the following website: www.SteinhoffSettlement.com .

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 19, 2021
Health sciences, Articles, Employee stock option, Life sciences, Employee compensation in the United States, Taxation in the United States, Inheritance, Labour law, Vesting, Therapy, Non-qualified stock option, Choline

b"NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Mart\xc3\xadn Sebastian Olivo, M.D., Protara\xe2\x80\x99s newly appointed Chief Medical Officer.\nEach stock option has an exercise price per share equal to $15.30 per share, Protara\xe2\x80\x99s closing trading price on April 19, 2021, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the individual\xe2\x80\x99s applicable vesting commencement date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee's continued service relationship with Protara through the applicable vesting dates.\nProtara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Key Points: 
  • b"NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Mart\xc3\xadn Sebastian Olivo, M.D., Protara\xe2\x80\x99s newly appointed Chief Medical Officer.\nEach stock option has an exercise price per share equal to $15.30 per share, Protara\xe2\x80\x99s closing trading price on April 19, 2021, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the individual\xe2\x80\x99s applicable vesting commencement date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee's continued service relationship with Protara through the applicable vesting dates.\nProtara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • Protara\xe2\x80\x99s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
  • For more information, visit www.protaratx.com.\n"

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Retrieved on: 
Thursday, September 5, 2019
Biotechnology, General Health, Oncology, Health, Medical devices, Clinical trials, Employee compensation in the United States, Employee stock option, Inheritance, Labour law, Property law, Vesting, Executive compensation, Law, Non-qualified stock option, Pulse, Private law, Academic disciplines

Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company), a novel bioelectric medicine company bringing to market its proprietary CellFX System, announced today that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 105,000 shares of Pulse Biosciences common stock to two recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 29, 2019.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company), a novel bioelectric medicine company bringing to market its proprietary CellFX System, announced today that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 105,000 shares of Pulse Biosciences common stock to two recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 29, 2019.
  • The options have an exercise price of $11.82 per share, which is equal to the closing price of Pulse Biosciences common stock on August 29, 2019.
  • Continued vesting for both option grants is subject to the recipients continued employment with Pulse Biosciences on the respective vesting dates.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that improves and extends the lives of patients.